Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis

BACKGROUND AND OBJECTIVES: To simulate the cost-effectiveness of Mesenchymal Stromal Cell (MSC) therapy compared to sodium/glucose co-transporter 2 inhibitors (SGLT2i) or usual care (UC) in treating patients with Diabetic Kidney Disease (DKD). DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: This Ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Barry, Luke E., Crealey, Grainne E., Cockwell, Paul, Elliman, Stephen J., Griffin, Matthew D., Maxwell, Alexander P., O’Brien, Timothy, Perico, Norberto, O’Neill, Ciaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635741/
https://www.ncbi.nlm.nih.gov/pubmed/36331936
http://dx.doi.org/10.1371/journal.pone.0274136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635741/
https://www.ncbi.nlm.nih.gov/pubmed/36331936
http://dx.doi.org/10.1371/journal.pone.0274136

Ejemplares similares